Your browser does not fully support modern features. Please upgrade for a smoother experience.
Drug Regimen after a Pneumonectomy: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lily Guo and Version 1 by Ronny Priefer.

Pneumonectomy is an entire lung removal and is indicated for both malignant and benign diseases.

  • pneumonectomy
  • Drug Regimen
  • non-small cell lung cancer
  • malignant pleural mesothelioma
  • tuberculosis
  • respiratory health
Please wait, diff process is still running!

References

  1. Gu, C.; Wang, R.; Pan, X.; Huang, Q.; Luo, J.; Zheng, J.; Wang, Y.; Shi, J.; Chen, H. Comprehensive study of prognostic risk factors of patients underwent pneumonectomy. J. Cancer 2017, 8, 2097–2103.
  2. Dogru, M.V.; Sezen, C.B.; Aker, C.; Girgin, O.; Kilimci, U.; Erduhan, S.; Metin, M. Evaluation of factors affecting morbidity and mortality in pneumonectomy patients. Acta Chir. Belg. 2020, 1–7.
  3. Rivera, C.; Arame, A.; Pricopi, C.; Riquet, M.; Mangiameli, G.; Abdennadher, M.; Dahan, M.; Barthes, F.L.P. Pneumonectomy for benign disease: Indications and postoperative outcomes, a nationwide study. Eur. J. Cardio Thorac. Surg. 2015, 48, 435–440.
  4. Stolz, A.J.; Harustiak, T.; Simonek, J.; Schutzner, J.; Lischke, R. Pneumonectomy for non-small cell lung cancer: Predictors of early mortality and morbidity. Acta Chir. Belg. 2014, 114, 25–30.
  5. Yang, C.-F.J.; Shah, S.A.; Lin, B.K.; VanDusen, K.W.; Chan, D.Y.; Tan, W.D.; Ranney, D.N.; Cox, M.L.; D’Amico, T.A.; Berry, M.F. Right-Sided Versus Left-Sided Pneumonectomy After Induction Therapy for Non-Small Cell Lung Cancer. Ann. Thorac. Surg. 2019, 107, 1074–1081.
  6. Darling, G.E.; Abdurahman, A.; Yi, Q.-L.; Johnston, M.; Waddell, T.K.; Pierre, A.; Keshavjee, S.; Ginsberg, R. Risk of a Right Pneumonectomy: Role of Bronchopleural Fistula. Ann. Thorac. Surg. 2005, 79, 433–437.
  7. Rakovich, G.; Bussieres, J.; Fréchette, E. Postpneumonectomy syndrome. Multimed. Man. Cardio Thorac. Surg. 2009, 2009.
  8. Shen, K.R.; Wain, J.C.; Wright, C.D.; Grillo, H.C.; Mathisen, D.J. Postpneumonectomy syndrome: Surgical management and long-term results. J. Thorac. Cardiovasc. Surg. 2008, 135, 1210–1219.
  9. Soll, C.; Hahnloser, D.; Frauenfelder, T.; Russi, E.W.; Weder, W.; Kestenholz, P.B. The postpneumonectomy syndrome: Clinical presentation and treatment. Eur. J. Cardio-Thorac. Surg. 2009, 35, 319–324.
  10. Shiraishi, Y.; Nakajima, Y.; Katsuragi, N.; Kurai, M.; Takahashi, N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2004, 128, 523–528.
  11. Mohsen, T.; Zeid, A.A.; Haj-Yahia, S. Lobectomy or pneumonectomy for multidrug-resistant pulmonary tuberculosis can be performed with acceptable morbidity and mortality: A seven-year review of a single institution’s experience. J. Thorac. Cardiovasc. Surg. 2007, 134, 194–198.
  12. Byun, C.S.; Chung, K.Y.; Narm, K.S.; Lee, J.G.; Hong, D.; Lee, C.Y. Early and Long-term Outcomes of Pneumonectomy for Treating Sequelae of Pulmonary Tuberculosis. Korean J. Thorac. Cardiovasc. Surg. 2012, 45, 110–115.
  13. Kim, Y.T.; Kim, H.K.; Sung, S.-W.; Kim, J.H. Long-term outcomes and risk factor analysis after pneumonectomy for active and sequela forms of pulmonary tuberculosis. Eur. J. Cardio Thorac. Surg. 2003, 23, 833–839.
  14. Matsushima, K.; Aiolfi, A.; Park, C.; Rosen, D.; Strumwasser, A.; Benjamin, E.; Inaba, K.; Demetriades, D. Surgical outcomes after trauma pneumonectomy. J. Trauma Acute Care Surg. 2017, 82, 927–932.
  15. Martin, M.J.; McDonald, J.M.; Mullenix, P.S.; Steele, S.R.; Demetriades, D. Operative Management and Outcomes of Traumatic Lung Resection. J. Am. Coll. Surg. 2006, 203, 336–344.
  16. Phillips, B.; Turco, L.; Mirzaie, M.; Fernandez, C. Trauma pneumonectomy: A narrative review. Int. J. Surg. 2017, 46, 71–74.
  17. Lubitz, A.L.; Sjoholm, L.O.; Goldberg, A.; Pathak, A.; Santora, T.; Sharp, T.E.; Wallner, M.; Berretta, R.M.; Poole, L.A.; Wu, J.; et al. Acute right heart failure after hemorrhagic shock and trauma pneumonectomy—A management approach. J. Trauma Acute Care Surg. 2017, 82, 243–251.
  18. Li, Z.; Chen, W.; Xia, M.; Liu, H.; Liu, Y.; Inci, I.; Davoli, F.; Waseda, R.; Filosso, P.L.; White, A. Sleeve lobectomy compared with pneumonectomy for operable centrally located non-small cell lung cancer: A meta-analysis. Transl. Lung Cancer Res. 2019, 8, 775–786.
  19. Kim, Y.T.; Kang, C.H.; Sung, S.W.; Kim, J.H. Local Control of Disease Related to Lymph Node Involvement in Non-Small Cell Lung Cancer After Sleeve Lobectomy Compared with Pneumonectomy. Ann. Thorac. Surg. 2005, 79, 1153–1161.
  20. Siripurapu, V.; Stitzenberg, K.B.; Nitzkorski, J.; Lebenthal, A.; Scott, W.J. Pneumonectomy for Cancer in the Mid-Atlantic US: Trends and Outcomes over a Decade. Chest 2010, 138, 659A.
  21. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30.
  22. Wang, G.; Liu, L.; Zhang, J.; Li, S. The analysis of prognosis factor in patients with non-small cell lung cancer receiving pneumonectomy. J. Thorac. Dis. 2020, 12, 1366–1373.
  23. Ilonen, I.K.; Räsänen, J.V.; Sihvo, E.I.; Knuuttila, A.; Sovijärvi, A.R.; Sintonen, H.; Salo, J.A. Pneumonectomy: Post-operative quality of life and lung function. Lung Cancer 2007, 58, 397–402.
  24. Kris, M.G.; Gaspar, L.E.; Chaft, J.E.; Kennedy, E.B.; Azzoli, C.G.; Ellis, P.M.; Lin, S.H.; Pass, H.I.; Seth, R.; Shepherd, F.A.; et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary. J. Clin. Oncol. 2017, 35, 2960–2974.
  25. Roselli, M.; Mariotti, S.; Ferroni, P.; Laudisi, A.; Mineo, D.; Pompeo, E.; Ambrogi, V.; Mineo, T.C. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. Int. J. Cancer 2006, 119, 955–960.
  26. Mineo, T.C.; Ambrogi, V.; Corsaro, V.; Roselli, M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur. J. Cardio Thorac. Surg. 2001, 20, 378–384.
  27. Jang, H.J.; Cho, S.; Kim, K.; Jheon, S.; Yang, H.C.; Kim, D.K. Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model. Cancer Res. Treat. 2017, 49, 898–905.
  28. Dediu, M.; Ion, O.; Ion, R.; Alexandru, A.; Median, D.; Gal, C.; Horvat, T.; Motas, C.; Motas, N. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: An analysis of 112 consecutively treated patients. JBUON J. Balk. Union Oncol. 2012, 17, 317–322.
  29. Park, S.Y.; Lee, J.G.; Kim, J.; Byun, G.E.; Bae, M.K.; Lee, C.Y.; Kim, D.J.; Chung, K.Y. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J. Cardiothorac. Surg. 2013, 8, 151.
  30. Li, R.; Yang, G.; Tian, Y.; Tian, D. Comparing the benefits of postoperative adjuvant chemotherapy vs. observation for stage IB non-small cell lung cancer: A meta-analysis. J. Thorac. Dis. 2019, 11, 3047–3054.
  31. Arriagada, R.; Auperin, A.; Burdett, S.; Higgins, J.; Johnson, D.; Le Chevalier, T.; Le Pechoux, C.; Mineo, T.; Parmar, M.; Pignon, J.; et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet 2010, 375, 1267–1277.
  32. Barton, M.K. Adjuvant chemotherapy benefits older and younger non-small cell lung cancer patients alike. CA Cancer J. Clin. 2012, 62, 279–280.
  33. Batum, Ö.; Anar, C.; Özdoğan, Y.; Ermin, S.; Yılmaz, U. Use of adjuvant chemotherapy for nonsmall cell lung cancer: Is advanced age a prognostic factor? Indian J. Cancer 2018, 55, 282.
  34. Wang, M.; Zhao, J.; Su, Y.-J.; Zhao, X.-L.; Wang, C.-L. Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer. Oncol. Lett. 2012, 4, 1349–1353.
  35. Tsukamoto, S.; Yamazaki, K.; Mori, R.; Katsura, M.; Kouso, H.; Kawano, D.; Ushijima, C.; Takeo, S. Feasibility Study for Biweekly Administration of Cisplatin plus Vinorelbine as Adjuvant-Chemotherapy for Completely Resected Non-Small Cell Lung Cancer Patients in a Japanese Population. Adv. Lung Cancer 2014, 3, 1–9.
  36. Hirai, F.; Seto, T.; Shimokawa, M.; Inamasu, E.; Toyozawa, R.; Toyokawa, G.; Yoshida, T.; Shiraishi, Y.; Takenaka, T.; Yamaguchi, M.; et al. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer. Anticancer. Res. 2014, 34, 927–931.
  37. Novello, S. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2015, 33, 3985–3986.
  38. Kelly, K.; Altorki, N.K.; Eberhardt, W.E.E.; O’Brien, M.E.; Spigel, D.R.; Crinò, L.; Tsai, C.-M.; Kim, J.-H.; Cho, E.K.; Hoffman, P.C.; et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. 2015, 33, 4007–4014.
  39. Wu, Y.-L.; Zhong, W.; Wang, Q.; Xu, S.-T.; Mao, W.-M.; Wu, L.; Shen, Y.; Liu, Y.-Y.; Chen, C.; Cheng, Y.; et al. Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). J. Clin. Oncol. 2017, 35, 8500.
  40. Lu, D.; Wang, Z.; Liu, X.; Feng, S.; Dong, X.; Shi, X.; Wang, H.; Wu, H.; Xiong, G.; Wang, H.; et al. Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: An updated meta-analysis. Cancer Manag. Res. 2019, 11, 2677–2690.
  41. Wu, Y.-L.; Tsuboi, M.; He, J.; John, T.; Grohe, C.; Majem, M.; Goldman, J.W.; Laktionov, K.; Kim, S.-W.; Kato, T.; et al. Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2020, 383, 1711–1723.
  42. Raphael, J.; Vincent, M.; Boldt, G.; Shah, P.S.; Rodrigues, G.; Blanchette, P. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non–Small Cell Lung Cancer (NSCLC). Am. J. Clin. Oncol. 2019, 42, 440–445.
  43. Huynh, C.; Walsh, L.A.; Spicer, J.D. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Transl. Lung Cancer Res. 2021, 10, 563–580.
  44. Brito, A.B.C.; Camandaroba, M.P.G.; de Lima, V.C.C. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. Thorac. Cancer 2021, 12, 1058–1066.
  45. Robinson, C.G.; Patel, A.; Bradley, J.D.; Waqar, S.N.; Morgensztern, D.; Baggstrom, M.Q.; Govindan, R.; Bell, J.; Guthrie, T.; Colditz, G.A.; et al. Postoperative radiotherapy (PORT) for pathologic N2 non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: A review of the National Cancer Database. J. Clin. Oncol. 2014, 32, 7509.
  46. Zeng, W.-Q.; Feng, W.; Xie, L.; Zhang, C.-C.; Yu, W.; Cai, X.-W.; Fu, X.-L. Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study. Lung 2019, 197, 741–751.
  47. Corso, C.D.; Rutter, C.E.; Wilson, L.D.; Kim, A.W.; Decker, R.H.; Husain, Z.A. Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database. J. Thorac. Oncol. 2015, 10, 148–155.
  48. Wang, W.; Men, Y.; Wang, J.; Zhou, Z.; Chen, D.; Xiao, Z.; Feng, Q.; Lv, J.; Liang, J.; Bi, N.; et al. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy. BMC Cancer 2019, 19, 478.
  49. Pöttgen, C.; Abu Jawad, J.; Gkika, E.; Freitag, L.; Lübcke, W.; Welter, S.; Gauler, T.; Schuler, M.; Eberhardt, W.E.E.; Stamatis, G.; et al. Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomy. J. Thorac. Dis. 2015, 7, 264–272.
  50. Ayub, A.; Rehmani, S.; Al-Ayoubi, A.M.; Lewis, E.; Santana-Rodríguez, N.; Clavo, B.; Raad, W.; Bhora, F.Y. Radiation therapy improves survival for unresectable postpneumonectomy lung tumors. J. Surg. Res. 2018, 227, 60–66.
  51. Testolin, A.; Favretto, M.S.; Cora, S.; Cavedon, C. Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: Dosimetric evaluation and pulmonary toxicity. Br. J. Radiol. 2015, 88, 20150228.
  52. Thompson, R.; Giuliani, M.; Yap, M.L.; Atallah, S.; Le, L.W.; Sun, A.; Brade, A.; Cho, B.J.; Bezjak, A.; Hope, A. Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy. J. Thorac. Oncol. 2014, 9, 843–847.
  53. Levra, N.G.; Filippi, A.R.; Guarneri, A.; Badellino, S.; Mantovani, C.; Ruffini, E.; Ricardi, U. Efficacy and Safety of Stereotactic Ablative Radiotherapy in Patients with Previous Pneumonectomy. Tumori J. 2015, 101, 148–153.
  54. Howlader, N.; Noone, A.M.; Krapcho, M.; Miller, D.; Brest, A.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.R.; et al. SEER Cancer Statistics Review, 1975–2017; National Cancer Institute: Bethesda, MD, USA, April 2020. Available online: (accessed on 20 July 2020).
  55. Filosso, P.L.; Guerrera, F.; Lausi, P.O.; Giobbe, R.; Lyberis, P.; Ruffini, E.; Oliaro, A. Pleurectomy/decortication versus extrapleural pneumonectomy: A critical choice. J. Thorac. Dis. 2018, 10, S390–S394.
  56. Magouliotis, D.E.; Tasiopoulou, V.S.; Athanassiadi, K. Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma. Gen. Thorac. Cardiovasc. Surg. 2018, 67, 312–320.
  57. Opitz, I.; Weder, W. A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma. Ann. Transl. Med. 2017, 5, 237.
  58. Marulli, G.; Faccioli, E.; Bellini, A.; Mammana, M.; Rea, F. Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma. Expert Rev. Respir. Med. 2017, 11, 649–660.
  59. Cao, C.; Tian, D.; Manganas, C.; Matthews, P.; Yan, T.D. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann. Cardiothorac. Surg. 2012, 1, 428–437.
  60. Takigawa, N.; Kiura, K.; Kishimoto, T. Medical Treatment of Mesothelioma: Anything New? Curr. Oncol. Rep. 2011, 13, 265–271.
  61. Tsao, A.S.; Wistuba, I.; Roth, J.A.; Kindler, H.L. Malignant Pleural Mesothelioma. J. Clin. Oncol. 2009, 27, 2081–2090.
  62. Mancuso, M.R.; Neal, J.W. Novel systemic therapy against malignant pleural mesothelioma. Transl. Lung Cancer Res. 2017, 6, 295–314.
  63. Ambrogi, V.; Baldi, A.; Schillaci, O.; Mineo, T.C. Clinical Impact of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Ann. Surg. Oncol. 2011, 19, 1692–1699.
  64. Batirel, H.F.; Metintas, M.; Caglar, H.B.; Yildizeli, B.; Lacin, T.; Bostanci, K.; Akgul, A.G.; Evman, S.; Yuksel, M. Trimodality Treatment of Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2008, 3, 499–504.
  65. Chen, S.E.; Pace, M.B.; Daniels, L.M.; Raasch, R.H.; Corbett, A.H. Malignant pleural mesothelioma. Am. J. Health Pharm. 2012, 69, 377–385.
  66. Patel, P.R.; Yoo, S.; Broadwater, G.; Marks, L.B.; Miles, E.F.; D’Amico, T.A.; Harpole, D.; Kelsey, C.R. Effect of Increasing Experience on Dosimetric and Clinical Outcomes in the Management of Malignant Pleural Mesothelioma With Intensity-Modulated Radiation Therapy. Int. J. Radiat. Oncol. 2012, 83, 362–368.
  67. Tonoli, S.; Vitali, P.; Scotti, V.; Bertoni, F.; Spiazzi, L.; Ghedi, B.; Buonamici, F.B.; Marrazzo, L.; Guidi, G.; Meattini, I.; et al. Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiother. Oncol. 2011, 101, 311–315.
  68. Luckraz, H.; Rahman, M.; Patel, N.; Szafranek, A.; Gibbs, A.R.; Butchart, E.G. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur. J. Cardio-Thorac. Surg. 2010, 37, 552–556.
  69. Garland, L.L.; Rankin, C.; Gandara, D.R.; Rivkin, S.E.; Scott, K.M.; Nagle, R.B.; Klein-Szanto, A.J.; Testa, J.R.; Altomare, D.A.; Borden, E.C. Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study. J. Clin. Oncol. 2007, 25, 2406–2413.
  70. Govindan, R.; Kratzke, R.A.; Herndon, J.E.; Niehans, G.A.; Vollmer, R.; Watson, D.; Green, M.R.; Kindler, H.L. Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B. Clin. Cancer Res. 2005, 11, 2300–2304.
  71. Jackman, D.M.; Kindler, H.L.; Yeap, B.Y.; Fidias, P.; Salgia, R.; Lucca, J.; Morse, L.K.; Ostler, P.A.; Johnson, B.E.; Jänne, P.A. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008, 113, 808–814.
  72. Porta, C.; Mutti, L.; Tassi, G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother. Pharmacol. 2006, 59, 149–150.
  73. Dudek, A.Z.; Pang, H.; Kratzke, R.A.; Otterson, G.A.; Hodgson, L.; Vokes, E.E.; Kindler, H.L. Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report. J. Thorac. Oncol. 2012, 7, 755–759.
  74. Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, D.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V.; et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 1405–1414.
  75. Grosso, F.; Steele, N.; Novello, S.; Nowak, A.K.; Popat, S.; Greillier, L.; John, T.; Leighl, N.B.; Reck, M.; Taylor, P.; et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. J. Clin. Oncol. 2017, 35, 3591–3600.
  76. Scagliotti, G.V.; Gaafar, R.; Nowak, A.K.; Nakano, T.; van Meerbeeck, J.; Popat, S.; Vogelzang, N.J.; Grosso, F.; Aboelhassan, R.; Jakopovic, M.; et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir. Med. 2019, 7, 569–580.
  77. Tsao, A.S.; Miao, J.; Wistuba, I.I.; Vogelzang, N.J.; Heymach, J.V.; Fossella, F.V.; Lu, C.; Velasco, M.R.; Box-Noriega, B.; Hueftle, J.G.; et al. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J. Clin. Oncol. 2019, 37, 2537–2547.
  78. Alley, E.W.; Lopez, J.; Santoro, A.; Morosky, A.; Saraf, S.; Piperdi, B.; van Brummelen, E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017, 18, 623–630.
  79. Metaxas, Y.; Rivalland, G.; Mauti, L.A.; Klingbiel, D.; Kao, S.; Schmid, S.; Nowak, A.K.; Gautschi, O.; Bartnick, T.; Hughes, B.G.; et al. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2018, 13, 1784–1791.
  80. Okada, M.; Kijima, T.; Aoe, K.; Kato, T.; Fujimoto, N.; Nakagawa, K.; Takeda, Y.; Hida, T.; Kanai, K.; Imamura, F.; et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin. Cancer Res. 2019, 25, 5485–5492.
  81. Quispel-Janssen, J.; van der Noort, V.; de Vries, J.F.; Zimmerman, M.; Lalezari, F.; Thunnissen, E.; Monkhorst, K.; Schouten, R.; Schunselaar, L.; Disselhorst, M.; et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2018, 13, 1569–1576.
  82. Hassan, R.; Thomas, A.; Nemunaitis, J.J.; Patel, M.R.; Bennouna, J.; Chen, F.L.; Delord, J.-P.; Dowlati, A.; Kochuparambil, S.T.; Taylor, M.H.; et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019, 5, 351–357.
  83. Popat, S.; Curioni-Fontecedro, A.; Dafni, U.; Shah, R.; O’Brien, M.; Pope, A.; Fisher, P.; Spicer, J.; Roy, A.; Gilligan, D.; et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 2020, 31, 1734–1745.
  84. Disselhorst, M.J.; Quispel-Janssen, J.; Lalezari, F.; Monkhorst, K.; de Vries, J.F.; van der Noort, V.; Harms, E.; Burgers, S.; Baas, P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 2019, 7, 260–270.
  85. Scherpereel, A.; Mazieres, J.; Greillier, L.; Lantuejoul, S.; Dô, P.; Bylicki, O.; Monnet, I.; Corre, R.; Audigier-Valette, C.; Locatelli-Sanchez, M.; et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019, 20, 239–253.
  86. Calabrò, L.; Morra, A.; Giannarelli, D.; Amato, G.; D’Incecco, A.; Covre, A.; Lewis, A.; Rebelatto, M.C.; Danielli, R.; Altomonte, M.; et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study. Lancet Respir. Med. 2018, 6, 451–460.
  87. Baldini, E.H.; Richards, W.G.; Gill, R.R.; Goodman, B.M.; Winfrey, O.K.; Eisen, H.M.; Mak, R.H.; Chen, A.B.; Kozono, D.E.; Bueno, R.; et al. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2015, 149, 1374–1381.
  88. Kostron, A.; Friess, M.; Crameri, O.; Inci, I.; Schneiter, D.; Hillinger, S.; Stahel, R.; Weder, W.; Opitz, I. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. Eur. J. Cardio-Thorac. Surg. 2015, 49, 1516–1523.
  89. Soldera, S.V.; Kavanagh, J.; Pintilie, M.; Leighl, N.B.; De Perrot, M.; Cho, J.; Hope, A.; Feld, R.; Bradbury, P.A. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Oncologist 2019, 24, e510–e517.
  90. WHO. Rapid Communication: Key Changes to Treatment of Drug-resistant Tuberculosis; WHO/CDS/TB/2019.26; World Health Organization: Geneva, Switzerland, December 2019.
  91. WHO. Global Tuberculosis Report 2019; World Health Organization: Geneva, Switzerland, 2019.
  92. Talwar, A.; Tsang, C.A.; Price, S.F.; Pratt, R.H.; Walker, W.L.; Schmit, K.M.; Langer, A.J. Tuberculosis-United States, 2018. MMWR. Morb. Mortal. Wkly. Rep. 2019, 68, 257–262.
  93. Dewan, R.K.; Pezzella, A.T. Surgical aspects of pulmonary tuberculosis: An update. Asian Cardiovasc. Thorac. Ann. 2016, 24, 835–846.
  94. Yablonskii, P.K.; Kudriashov, G.G.; Avetisyan, A.O. Surgical Resection in the Treatment of Pulmonary Tuberculosis. Thorac. Surg. Clin. 2019, 29, 37–46.
  95. Yablonskiy, P.K.; Vasil’ev, I.V.; Kirjuhina, L.D. Immediate results of pneumonectomies in patients with unilateral localization of destructive pulmonary tuberculosis. Results of the prospective, non-randomized study. Med. Al’yans 2017, 4, 103–111. (In Russian)
  96. Harris, R.C.; Khan, M.S.; Martin, L.J.; Allen, V.; Moore, D.A.J.; Fielding, K.; Grandjean, L. The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: A systematic review and meta-analysis. BMC Infect. Dis. 2016, 16, 262.
  97. Vashakidze, S.; Gogishvili, S.; Nikolaishvili, K.; Dzidzikashvili, N.; Tukvadze, N.; Blumberg, H.M.; Kempker, R.R. Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery. Ann. Thorac. Surg. 2013, 95, 1892–1898.
  98. Kang, M.-W.; Kim, H.K.; Choi, Y.S.; Kim, K.; Shim, Y.M.; Koh, W.-J.; Kim, J. Surgical Treatment for Multidrug-Resistant and Extensive Drug-Resistant Tuberculosis. Ann. Thorac. Surg. 2010, 89, 1597–1602.
  99. Yaldiz, S.; Gursoy, S.; Ucvet, A.; Kaya, S.O. Surgery Offers High Cure Rates in Multidrug-resistant Tuberculosis. Ann. Thorac. Cardiovasc. Surg. 2011, 17, 143–147.
  100. Shiraishi, Y.; Katsuragi, N.; Kita, H.; Tominaga, Y.; Kariatsumari, K.; Onda, T. Aggressive surgical treatment of multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2009, 138, 1180–1184.
  101. Wang, H.; Lin, H.; Jiang, G. Pulmonary Resection in the Treatment of Multidrug-Resistant Tuberculosis: A Retrospective Study of 56 Cases. Ann. Thorac. Surg. 2008, 86, 1640–1645.
  102. Kir, A.; Inci, I.; Torun, T.; Atasalihi, A.; Tahaoglu, K. Adjuvant resectional surgery improves cure rates in multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2006, 131, 693–696.
  103. Naidoo, R.; Reddi, A. Lung Resection for Multidrug-Resistant Tuberculosis. Asian Cardiovasc. Thorac. Ann. 2005, 13, 172–174.
  104. Park, S.K.; Lee, C.M.; Heu, J.P.; Song, S.D. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2002, 6, 143–149.
  105. Lakshmanan, M.; Xavier, A.S. Bedaquiline—The first ATP synthase inhibitor against multi drug resistant tuberculosis. J. Young Pharm. 2013, 5, 112–115.
  106. Charan, J.; Reljic, T.; Kumar, A. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review. Indian J. Pharmacol. 2016, 48, 186–191.
  107. Salinger, D.H.; Nedelman, J.R.; Mendel, C.; Spigelman, M.; Hermann, D.J. Daily Dosing for Bedaquiline in Patients with Tuberculosis. Antimicrob. Agents Chemother. 2019, 63, 11.
  108. Diacon, A.H.; Dawson, R.; Hanekom, M.; Narunsky, K.; Venter, A.; Hittel, N.; Geiter, L.J.; Wells, C.D.; Paccaly, A.J.; Donald, P.R. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 2011, 15, 949–954.
  109. Conradie, F.; Diacon, A.H.; Ngubane, N.; Howell, P.; Everitt, D.; Crook, A.M.; Mendel, C.M.; Egizi, E.; Moreira, J.; Timm, J.; et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N. Engl. J. Med. 2020, 382, 893–902.
  110. Eren, Ş.; Eren, M.N.; Balcı, A.E. Pneumonectomy in children for destroyed lung and the long-term consequences. J. Thorac. Cardiovasc. Surg. 2003, 126, 574–581.
  111. Bai, L.; Hong, Z.; Gong, C.; Yan, D.; Liang, Z. Surgical treatment efficacy in 172 cases of tuberculosis-destroyed lungs. Eur. J. Cardio-Thorac. Surg. 2011, 41, 335–340.
  112. Luzzi, L.; Tenconi, S.; Voltolini, L.; Paladini, P.; Ghiribelli, C.; Di Bisceglie, M.; Gotti, G. Long-term respiratory functional results after pneumonectomy. Eur. J. Cardio-Thorac. Surg. 2008, 34, 164–168.
  113. Fernández, L.G.; Isbell, J.M.; Jones, D.R.; Laubach, V.E. Compensatory lung growth after pneumonectomy. In Topics in Thoracic Surgery; Guerreiro, C., Paulo, F., Eds.; IntechOpen: Sao Pablo, Brazil, 2012; pp. 415–431.
  114. Kaza, A.K.; Laubach, V.E.; Kern, J.A.; Long, S.M.; Fiser, S.M.; Tepper, J.A.; Nguyen, R.P.; Shockey, K.S.; Tribble, C.G.; Kron, I.L. Epidermal growth factor augments postpneumonectomy lung growth. J. Thorac. Cardiovasc. Surg. 2000, 120, 916–922.
  115. Dao, D.T.; Anez-Bustillos, L.; Adam, R.M.; Puder, M.; Bielenberg, D.R. Heparin-Binding Epidermal Growth Factor–Like Growth Factor as a Critical Mediator of Tissue Repair and Regeneration. Am. J. Pathol. 2018, 188, 2446–2456.
  116. Matsui, Y.; Amano, H.; Ito, Y.; Eshima, K.; Tamaki, H.; Ogawa, F.; Iyoda, A.; Shibuya, M.; Kumagai, Y.; Satoh, Y.; et al. The role of vascular endothelial growth factor receptor-1 signaling in compensatory contralateral lung growth following unilateral pneumonectomy. Lab. Investig. 2015, 95, 456–468.
  117. Sakurai, M.K.; Lee, S.; Arsenault, D.A.; Nose, V.; Wilson, J.M.; Heymach, J.V.; Puder, M. Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am. J. Physiol. Cell. Mol. Physiol. 2007, 292, L742–L747.
  118. Kaza, A.K.; Kron, I.L.; Leuwerke, S.M.; Tribble, C.G.; E Laubach, V. Keratinocyte growth factor enhances post-pneumonectomy lung growth by alveolar proliferation. Circulation 2002, 106, I-120.
  119. Sakamaki, Y.; Matsumoto, K.; Mizuno, S.; Miyoshi, S.; Matsuda, H.; Nakamura, T. Hepatocyte Growth Factor Stimulates Proliferation of Respiratory Epithelial Cells during Postpneumonectomy Compensatory Lung Growth in Mice. Am. J. Respir. Cell Mol. Biol. 2002, 26, 525–533.
  120. Dao, D.T.; Anez-Bustillos, L.; Jabbouri, S.S.; Pan, A.; Kishikawa, H.; Mitchell, P.D.; Fell, G.L.; Baker, M.A.; Watnick, R.S.; Chen, H.; et al. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS ONE 2018, 13, e0208579.
  121. Dane, D.M.; Yilmaz, C.; Gyawali, D.; Iyer, R.; Menon, J.U.; Nguyen, K.T.; Ravikumar, P.; Estrera, A.S.; Hsia, C.C.W. Erythropoietin inhalation enhances adult canine alveolar-capillary formation following pneumonectomy. Am. J. Physiol. Cell. Mol. Physiol. 2019, 316, L936–L945.
  122. Takahashi, Y.; Izumi, Y.; Kohno, M.; Kimura, T.; Kawamura, M.; Okada, Y.; Nomori, H.; Ikeda, E. Thyroid Transcription Factor-1 Influences the Early Phase of Compensatory Lung Growth in Adult Mice. Am. J. Respir. Crit. Care Med. 2010, 181, 1397–1406.
  123. Takahashi, Y.; Izumi, Y.; Kohno, M.; Kawamura, M.; Ikeda, E.; Nomori, H. Airway administration of dexamethasone, 3′-5′-cyclic adenosine monophosphate, and isobutylmethylxanthine facilitates compensatory lung growth in adult mice. Am. J. Physiol. Cell. Mol. Physiol. 2011, 300, L453–L461.
  124. Lechner, A.J.; Driver, I.H.; Lee, J.; Conroy, C.M.; Nagle, A.; Locksley, R.M.; Rock, J.R. Recruited Monocytes and Type 2 Immunity Promote Lung Regeneration following Pneumonectomy. Cell Stem Cell 2017, 21, 120–134.
  125. Mammoto, T.; Chen, Z.; Jiang, A.; Jiang, E.; Ingber, N.E.; Mammoto, A. Acceleration of Lung Regeneration by Platelet-Rich Plasma Extract through the Low-Density Lipoprotein Receptor-Related Protein 5-Tie2 Pathway. Am. J. Respir. Cell Mol. Biol. 2016, 54, 103–113.
  126. Edvardsen, E.; Skjonsberg, O.H.; Holme, I.; Nordsletten, L.; Borchsenius, F.; Anderssen, S.A. High-intensity training following lung cancer surgery: A randomised controlled trial. Thorax 2015, 70, 244–250.
  127. Kendall, F.; Abreu, P.; Pinho, P.; Oliveira, J.; Bastos, P. The role of physiotherapy in patients undergoing pulmonary surgery for lung cancer. A literature review. Rev. Port. De Pneumol. 2017, 23, 343–351.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback

Quick Survey

Encyclopedia MDPI is conducting a targeted survey to identify the specific barriers hindering efficient research. We invite you to spend 3 minutes defining the priorities for our next generation of structured knowledge tools.
Take Survey